<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23243" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hyperuricemia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>George</surname>
            <given-names>Christina</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Leslie</surname>
            <given-names>Stephen W.</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Minter</surname>
            <given-names>David A.</given-names>
          </name>
          <aff>MSU-McLaren Oakland</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Christina George declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Stephen Leslie declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>David Minter declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>14</day>
          <month>10</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23243.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hyperuricemia is a common disorder that affects patients of all ages and genders. The most common manifestation of hyperuricemia is gout, which can be very painful and is amenable to treatment. Hyperuricemia is also associated with uric acid and calcium nephrolithiasis. Hyperuricemia affects about 38 million Americans, over 11% of the population, and the incidence is increasing worldwide.</p>
        <p>Most patients with hyperuricemia are asymptomatic, and the diagnosis requires a high degree of suspicion as serum uric acid levels are no longer routinely measured on serum blood panels. Patients with hyperuricemia who develop gout are usually best treated with a xanthine oxidase inhibitor like allopurinol. Depending on the urinary chemistry and stone type, allopurinol, potassium citrate, or both may be recommended in nephrolithiasis.&#x000a0;</p>
        <p>This activity reviews the pathophysiology, presentation, evaluation, and treatment of hyperuricemia, as well as highlights the interprofessional team's role in caring for affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Recognize individuals at risk of hyperuricemia by evaluating dietary habits, family history, and lifestyle factors, and regularly monitor serum uric acid levels.</p></list-item><list-item><p>Initiate evidence-based management strategies, including lifestyle modifications, pharmacotherapy, and dietary interventions, to effectively control uric acid levels and reduce the risk of associated complications.</p></list-item><list-item><p>Identify treatment modalities for both acute and chronic hyperuricemia.</p></list-item><list-item><p>Facilitate coordinated care by ensuring seamless transitions&#x000a0;among primary care, specialty care, and other healthcare providers, providing comprehensive management of hyperuricemia and its associated comorbidities.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23243&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23243">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23243.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Hyperuricemia is defined as an elevated serum uric acid level, usually greater than 6 mg/dL in women and 7 mg/dL in men. Elevated serum uric acid is present in an estimated 38 million Americans, and the incidence is increasing worldwide as developing countries adopt more Western diets and lifestyles. Most people with this condition will not have obvious clinical manifestations, however, it is unclear what the long-term effects of hyperuricemia are on overall cardiovascular health, renal function, and overall morbidity.<xref ref-type="bibr" rid="article-23243.r1">[1]</xref>&#x000a0;Hyperuricemia results from increased uric acid production, decreased excretion, or a combination of both processes.&#x000a0;</p>
        <p>Dietary purines are responsible for about one-third of the body's daily serum uric acid production; the rest is synthesized from endogenous sources. Elevated uric acid can also be seen with accelerated purine degradation in high cell turnover states (eg, hemolysis, rhabdomyolysis, tumor lysis) and decreased excretion (eg, genetic disorders, renal insufficiency, metabolic syndrome). About two-thirds of uric acid is excreted through the kidney and one-third through the gastrointestinal (GI) tract. However, these proportions can change depending on medications or dysfunction in the renal or GI systems.</p>
        <p>Most people with hyperuricemia are asymptomatic (85% to 90%), but elevated uric acid levels in the blood or urine can lead to gout or nephrolithiasis. Hyperuricemia and hyperuricosuria have also been linked with other disorders such as metabolic syndrome, diabetes mellitus, cardiovascular disease, hypertension, atherosclerosis, obesity, and chronic renal disease.<xref ref-type="bibr" rid="article-23243.r2">[2]</xref><xref ref-type="bibr" rid="article-23243.r3">[3]</xref><xref ref-type="bibr" rid="article-23243.r4">[4]</xref><xref ref-type="bibr" rid="article-23243.r5">[5]</xref><xref ref-type="bibr" rid="article-23243.r6">[6]</xref></p>
      </sec>
      <sec id="article-23243.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>
<bold>Uric Acid Overproduction</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Purine-rich diet: alcohol (especially beer); bacon; beef; lamb; turkey; veal; venison; organ meats; and certain fish and shellfish (anchovies, cod, tuna, sardines, herring, mussels, shrimp, lobster, codfish, scallops, trout, and haddock)</p>
          </list-item>
          <list-item>
            <p>Fructose causes hyperuricemia as its hepatic metabolism through the aldolase reductase pathway produces uric acid. High-fructose corn syrup and full-sugar sodas are especially harmful and are associated with obesity in children and adolescents.&#x000a0;<xref ref-type="bibr" rid="article-23243.r7">[7]</xref><xref ref-type="bibr" rid="article-23243.r8">[8]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Errors of purine metabolism: hypoxanthine-guanine phosphoribosyltransferase (HPRT or HGPRT) deficiency, phosphoribosylpyrophosphate (PRPP) synthetase overactivity.</p>
          </list-item>
          <list-item>
            <p>High cell breakdown or turnover: lymphoproliferative diseases, myeloproliferative disease, polycythemia vera, Paget disease, psoriasis, tumor lysis, hemolysis, rhabdomyolysis, extreme exercise, chemotherapy.</p>
          </list-item>
        </list>
        <p>
<bold>Decreased Uric Acid Excretion</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute or chronic kidney disease, acidosis (eg, lactic acidosis, ketoacidosis), hypovolemia, medication/toxins (diuretics, niacin, pyrazinamide, ethambutol, cyclosporine, beryllium, salicylates, lead, alcohol), sarcoidosis, hyperparathyroidism, hypothyroidism, Bartter syndrome, Down syndrome.<xref ref-type="bibr" rid="article-23243.r9">[9]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Diuretic-induced Hyperuricemia</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Thiazide and loop diuretics tend to cause a dose-dependent type of hyperuricemia and possibly even gout.<xref ref-type="bibr" rid="article-23243.r10">[10]</xref><xref ref-type="bibr" rid="article-23243.r11">[11]</xref><xref ref-type="bibr" rid="article-23243.r12">[12]</xref>&#x000a0;They tend to increase renal uric acid reabsorption either directly or indirectly through volume depletion.<xref ref-type="bibr" rid="article-23243.r10">[10]</xref><xref ref-type="bibr" rid="article-23243.r12">[12]</xref><xref ref-type="bibr" rid="article-23243.r13">[13]</xref><xref ref-type="bibr" rid="article-23243.r14">[14]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The net increase in relative risk of gout by diuretics is almost 80%.<xref ref-type="bibr" rid="article-23243.r15">[15]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>An alternate or concurrent antihypertensive, including an angiotensin II receptor blocker (especially losartan) or an&#x000a0;angiotensin-converting enzyme inhibitor, is recommended in patients with gout flares.<xref ref-type="bibr" rid="article-23243.r16">[16]</xref><xref ref-type="bibr" rid="article-23243.r17">[17]</xref><xref ref-type="bibr" rid="article-23243.r18">[18]</xref><xref ref-type="bibr" rid="article-23243.r19">[19]</xref><xref ref-type="bibr" rid="article-23243.r20">[20]</xref><xref ref-type="bibr" rid="article-23243.r21">[21]</xref><xref ref-type="bibr" rid="article-23243.r22">[22]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Most patients with diuretic-induced gout are treated with a xanthine oxidase inhibitor, such as allopurinol. However, if the patient is asymptomatic, no treatment is needed.&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23243.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Up to 21% of the general population and 25% of hospitalized patients are estimated to have asymptomatic hyperuricemia, and uric acid levels can be elevated 10 to 15 years before clinical manifestations of gout.<xref ref-type="bibr" rid="article-23243.r23">[23]</xref><xref ref-type="bibr" rid="article-23243.r24">[24]</xref>&#x000a0;Hyperuricemia does not indicate a pathological state because&#x000a0;it is extremely prevalent in the general population and is asymptomatic in 90% to 95% of people.<xref ref-type="bibr" rid="article-23243.r25">[25]</xref>&#x000a0;The worldwide incidence of hyperuricemia is increasing in economically advantaged countries and the developing world as they adopt a Western diet and lifestyle.<xref ref-type="bibr" rid="article-23243.r23">[23]</xref><xref ref-type="bibr" rid="article-23243.r26">[26]</xref>&#x000a0;Hyperuricemia is particularly high in Pacific islanders.<xref ref-type="bibr" rid="article-23243.r27">[27]</xref>&#x000a0;Men have higher rates than women, as estrogen is protective against hyperuricemia, and women can develop hyperuricemia after menopause.<xref ref-type="bibr" rid="article-23243.r28">[28]</xref><xref ref-type="bibr" rid="article-23243.r29">[29]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-23243.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>
<bold>Clinical Manifestations</bold>
</p>
        <p>Gout&#x000a0;is a metabolic disorder that allows for the accumulation of uric acid in the blood and tissues. This leads to the precipitation of urate monohydrate crystals within a joint. Crystal deposition is enhanced in acidic and cold environments, leading to gout manifestations in peripheral joints, such as the big toe. Gout has a male predominance in a 4:1 ratio of men to women.<xref ref-type="bibr" rid="article-23243.r24">[24]</xref></p>
        <p>In uric acid nephrolithiasis, uric acid precipitates in the urine, most commonly due to acidic urine and metabolic syndrome. Acidic urine, hypovolemia, and hyperuricosuria are the most significant risk factors for uric acid nephrolithiasis. Hyperuricosuria is defined as uric acid levels that exceed 800 mg/day in men and 750 mg/day in women. Uric acid stones comprise 5% to 10% of all urinary stones and can also have calcium components.<xref ref-type="bibr" rid="article-23243.r30">[30]</xref></p>
        <p>Hypertension is linked to hyperuricemia, even when adjusted for comorbidities of obesity and diabetes.<xref ref-type="bibr" rid="article-23243.r29">[29]</xref><xref ref-type="bibr" rid="article-23243.r31">[31]</xref><xref ref-type="bibr" rid="article-23243.r32">[32]</xref>&#x000a0;A large cross-sectional study showed that even at levels considered within the normal range (&#x02265;5.3 mg/dL in men, and&#x000a0;&#x02265;4.3 mg/dL in women), serum uric acid levels were directly related to hypertension after adjusting for other comorbidities. Mechanisms by which hyperuricemia may cause hypertension include activation of the renin-angiotensin system, oxidative stress, endothelial inflammation, endothelin-1 activation, and nitrous oxide reduction.<xref ref-type="bibr" rid="article-23243.r31">[31]</xref><xref ref-type="bibr" rid="article-23243.r33">[33]</xref></p>
        <p>Obesity and hyperuricemia are also highly linked, and some analyses suggest that obesity is a cause of hyperuricemia. Proposed mechanisms are (1) visceral adipose tissue providing free fatty acids to the liver, inducing uric acid production and (2) dysregulation of adipocytes causing decreased uric acid and sodium excretion by the renal tubules. Small clinical trials have shown that urate-lowering drugs may decrease the development of hypertension in adolescents; however, these drugs can have serious adverse effects, so this is not recommended as treatment.<xref ref-type="bibr" rid="article-23243.r31">[31]</xref></p>
        <p>Hyperuricemia is also highly associated with cardiac and renal disease. However, given the significant overlap&#x000a0;among the risk factors for all&#x000a0;3 disease states, it is difficult to determine cause and effect.<xref ref-type="bibr" rid="article-23243.r32">[32]</xref><xref ref-type="bibr" rid="article-23243.r33">[33]</xref>&#x000a0;One prospective study found that urate-lowering therapy did not decrease the development of CKD and was actually associated with worse kidney outcomes, so urate-lowering drugs are not indicated for primary prevention of kidney disease.<xref ref-type="bibr" rid="article-23243.r34">[34]</xref><xref ref-type="bibr" rid="article-23243.r35">[35]</xref></p>
        <p>
<bold>Mechanisms of Hyperuricemia</bold>
</p>
        <p>Uric acid (2,6,8 thiopurine-C5H4N4O3) is the result of purine breakdown. At the normal physiological pH of 7.4, uric acid circulates in the ionized form of urate. Purine metabolism mainly occurs in the liver but can also happen in any tissue containing xanthine oxidase, such as cardiac or pulmonary tissue.&#x000a0;About two-thirds of the body's total production of uric acid is excreted in the kidneys, and a third&#x000a0;is passed into the intestine. Urate is filtered and secreted in the kidneys, then 90% is reabsorbed in the proximal tubule. Other mammals have much lower uric acid levels due to the activity of uricase, which converts urate to the more water-soluble allantoin. However, in humans and higher primates, this enzyme is nonfunctional.<xref ref-type="bibr" rid="article-23243.r36">[36]</xref></p>
        <p>Purine-rich diets, endogenous purine production, and high cell breakdown accelerate uric acid production. Beer, which is high in purines, especially increases uric acid levels.<xref ref-type="bibr" rid="article-23243.r37">[37]</xref> Endogenous production of the purine production can be accelerated by phosphoribosylpyrophosphate (PRPP) synthetase activity and a defect in the regulatory enzyme hypoxanthine-guanine phosphoribosyltransferase (HPRT).<xref ref-type="bibr" rid="article-23243.r38">[38]</xref><xref ref-type="bibr" rid="article-23243.r39">[39]</xref>&#x000a0;Accelerated cell breakdown or turnover conditions include rhabdomyolysis, hemolysis,&#x000a0;psoriasis, myeloproliferative disorders, and tumor lysis.<xref ref-type="bibr" rid="article-23243.r40">[40]</xref></p>
        <p>
<bold>Urate Transport in the Kidney</bold>
</p>
        <p>Urate excretion occurs primarily in the kidneys, and impaired urinary excretion is responsible for hyperuricemia in 90% of individuals. Underexcretion is a combination of decreased glomerular filtration, reduced tubular secretion, and enhanced tubular reabsorption.&#x000a0;</p>
        <p>Proximal tubular reabsorption of uric acid is controlled by uric acid transporter 1 (URAT1) located in the apical cell membrane.<xref ref-type="bibr" rid="article-23243.r41">[41]</xref><xref ref-type="bibr" rid="article-23243.r42">[42]</xref>&#x000a0;This transporter can be stimulated by organic acids (lactate, acetoacetate, and beta-hydroxybutyrate), medications (niacin, pyrazinamide, ethambutol, cyclosporin, and chemotherapeutic agents), and reduced extracellular fluid volume resulting in hyperuricemia.<xref ref-type="bibr" rid="article-23243.r2">[2]</xref>&#x000a0;URAT1 inhibitors are the most effective class of uricosuric agents available to treat hyperuricemia.<xref ref-type="bibr" rid="article-23243.r41">[41]</xref>&#x000a0;Urate is then transported into the renal interstitium by the GLUT9 transporter.<xref ref-type="bibr" rid="article-23243.r42">[42]</xref></p>
      </sec>
      <sec id="article-23243.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Hyperuricemia can be visualized when monosodium urate crystals precipitate. Joint precipitation appears as the classic "needle-shaped crystals" seen in aspirated synovial fluid. Urinary uric acid will form crystals if urine pH is acidic (&#x0003c;5.5). These yellowish-brown crystals can be rhomboid or cluster to create a rosette shape.</p>
      </sec>
      <sec id="article-23243.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>History</bold>
</p>
        <p>Hyperuricemia alone is not a specific indication for therapy (despite evidence linking it to the development of diabetes, hypertension, and cardiac disease). Most patients with elevated uric acid are asymptomatic and require no long-term therapy. The&#x000a0;patient may give a history of a purine-rich diet or high alcohol consumption. Past medical history and current medications should be carefully reviewed for any correlation with poor renal excretion of urate or increased uric acid production.</p>
        <p>Gout and uric acid nephrolithiasis are the&#x000a0;2 most common complaints associated with hyperuricemia. During&#x000a0;a gout attack, the patient complains of red, hot, swollen joints, often including the big toe (podagra).<xref ref-type="bibr" rid="article-23243.r43">[43]</xref>&#x000a0;The presentation of nephrolithiasis includes renal colic or severe, acute flank, abdominal, or back pain, often radiating to the groin; hematuria or brownish-colored urine; dysuria; and nausea and vomiting. Urinary tract symptoms, including fever, cloudy urine, and frequent urination, may also be present.<xref ref-type="bibr" rid="article-23243.r44">[44]</xref></p>
        <p>
<bold>Physical Exam</bold>
</p>
        <p>No specific physical exam findings will indicate hyperuricemia unless the patient presents with symptoms of acute gout attack or uric acid nephrolithiasis. With gout, there is evidence of an erythematous, warm, and swollen joint, most commonly affecting the big toe, but it can be present in any joint. Usually, gout affects only one joint at a time. Classically, this presents as "pain out of proportion to exam." Nephrolithiasis has no specific physical exam findings but may have reproducible costovertebral angle tenderness.&#x000a0;</p>
      </sec>
      <sec id="article-23243.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>Laboratory Studies</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Elevated serum uric acid&#x02014;normal values are typically less than 6.8 mg/dL and may vary by gender. Readings of 8 mg/dL or more are diagnostic of hyperuricemia.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>If nephrolithiasis is present, urinalysis may show microscopic hematuria, uric acid crystals, and low urinary pH (&#x0003c;5.5).</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>A 24-hour urine uric acid collection should be optimally less than 600 mg/day on a low-purine diet. A level greater than 800 mg/d identifies hyperuricosuria but does not designate whether the cause is related to increased production or decreased excretion of uric acid.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Other studies include a complete blood count (CBC) with differential, CMP, lipid profile, HgA1c, calcium, and phosphate levels. These laboratory studies are&#x000a0;useful in assessing underlying diseases such as malignancy, sickle cell disease, diabetes, and metabolic syndrome.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Consider joint x-rays to evaluate any unexplained swelling; however, x-ray findings are not required to diagnose gout.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Renal ultrasounds or noncontrast CT scans are indicated in patients with suspected uric acid nephrolithiasis. The use of IV contrast can obscure the presence of stones.</p>
          </list-item>
        </list>
        <p>
<bold>Procedures</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Consider joint aspiration to evaluate for uric acid crystals, which are needle-shaped and negatively birefringent under polarized microscopy.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23243.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Most patients with hyperuricemia are asymptomatic and do not need medical therapy, except for patients undergoing cytolytic therapy for malignancy to prevent tumor lysis syndrome.<xref ref-type="bibr" rid="article-23243.r45">[45]</xref><xref ref-type="bibr" rid="article-23243.r46">[46]</xref><xref ref-type="bibr" rid="article-23243.r47">[47]</xref><xref ref-type="bibr" rid="article-23243.r48">[48]</xref>&#x000a0;This recommendation is based on the cost of unnecessary medications and the potential for adverse effects, which generally outweigh the benefit of starting medication in asymptomatic patients.</p>
        <p>The American College of Rheumatology recommends that patients with&#x000a0;2 or more gout attacks a year should be treated, but a lower threshold can be used based on the severity of the gout flares and patient preference.<xref ref-type="bibr" rid="article-23243.r49">[49]</xref>&#x000a0;Other indications for treatment include&#x000a0;gouty bone erosion, structural joint injury, polyarticular disease, hyperuricosuric nephrolithiasis, and tophi.</p>
        <p><bold>Colchicine</bold> is frequently used to treat acute gout.<xref ref-type="bibr" rid="article-23243.r50">[50]</xref><xref ref-type="bibr" rid="article-23243.r51">[51]</xref>&#x000a0;It binds the tubulin protein, preventing microtubule formation and polymerization. It also has anti-inflammatory and anti-fibrotic effects.<xref ref-type="bibr" rid="article-23243.r52">[52]</xref>&#x000a0;See our companion StatPearls reference article on "Colchicine."<xref ref-type="bibr" rid="article-23243.r50">[50]</xref>&#x000a0;Patients starting uric acid lowering therapy should be considered for prophylactic colchicine to minimize the risk of an acute gouty flare. Slowly introducing hyperuricemia medications can also decrease the risk of gout flare attacks.<xref ref-type="bibr" rid="article-23243.r53">[53]</xref></p>
        <p>There are three types of uric acid-lowering medications: uricosuric agents, xanthine oxidase inhibitors, and recombinant uricases. Among these, only five are FDA-approved for use in the US: allopurinol, febuxostat, probenecid, rasburicase, and pegloticase.</p>
        <p><bold>Uricosuric agents</bold> work by increasing the renal and urinary excretion of uric acid. Normally, 10% of filtered uric acid is excreted in the urine. Uricosuric agents work by inhibiting the URAT1&#x000a0;anion-exchanging uric acid transporter system in the brush border of renal proximal tubular cells.<xref ref-type="bibr" rid="article-23243.r54">[54]</xref> This causes increased urinary excretion with a corresponding drop in serum uric acid levels. These agents are&#x000a0;not generally suitable for patients with hyperuricosuric nephrolithiasis and are most useful when urinary uric acid is less than 800 mg daily.</p>
        <p>Losartan, atorvastatin, and fenofibrate have mild uricosuric effects and can be considered adjunctive agents in patients with hypertension (losartan) or hyperlipidemia (atorvastatin, fenofibrate).<xref ref-type="bibr" rid="article-23243.r16">[16]</xref><xref ref-type="bibr" rid="article-23243.r55">[55]</xref><xref ref-type="bibr" rid="article-23243.r56">[56]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p><bold><bold>&#x000a0;</bold></bold><bold>Probenecid</bold> inhibits URAT1 and several other anion transporters, increasing renal uric acid excretion by reducing reabsorption.<xref ref-type="bibr" rid="article-23243.r57">[57]</xref>&#x000a0;It is typically used as second-line therapy for gout as it is considered less potent than other uric acid-lowering medications.<xref ref-type="bibr" rid="article-23243.r58">[58]</xref>&#x000a0;Probenecid can be used in patients who cannot tolerate xanthine oxidase inhibitors and is often used with colchicine for gout prophylaxis. It has many drug interactions limiting its clinical use.<xref ref-type="bibr" rid="article-23243.r58">[58]</xref><xref ref-type="bibr" rid="article-23243.r59">[59]</xref>&#x000a0;Probenecid can also increase the incidence of uric acid nephrolithiasis, so this should be closely monitored. It is also relatively contraindicated in patients with grade 3 or higher CKD.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Benzbromarone</bold>&#x000a0;is a URAT1 inhibitor type uricosuric drug used for gout and hyperuricemia in some countries but was unapproved in the US and Europe due to hepatotoxicity.<xref ref-type="bibr" rid="article-23243.r60">[60]</xref><xref ref-type="bibr" rid="article-23243.r61">[61]</xref>&#x000a0;While it is a potent URAT1 inhibitor and a more effective uricosuric agent than probenecid, it has low selectivity.<xref ref-type="bibr" rid="article-23243.r60">[60]</xref><xref ref-type="bibr" rid="article-23243.r62">[62]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>&#x000a0;<bold>Dotinurad</bold> is a highly selective URAT1 inhibitor and effective uricosuric agent available only in Japan that appears to be equivalent to benzbromarone and febuxostat in overall uric acid-lowering ability.<xref ref-type="bibr" rid="article-23243.r63">[63]</xref><xref ref-type="bibr" rid="article-23243.r64">[64]</xref><xref ref-type="bibr" rid="article-23243.r65">[65]</xref><xref ref-type="bibr" rid="article-23243.r66">[66]</xref><xref ref-type="bibr" rid="article-23243.r67">[67]</xref>&#x000a0;It is being evaluated for possible approval in the US and Europe.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Lesinurad </bold>is&#x000a0;another uricosuric URAT1 inhibito<bold>r</bold> drug that significantly increases urinary uric acid excretion, thereby substantially lowering serum uric acid levels.<xref ref-type="bibr" rid="article-23243.r68">[68]</xref><xref ref-type="bibr" rid="article-23243.r69">[69]</xref><xref ref-type="bibr" rid="article-23243.r70">[70]</xref>&#x000a0;The manufacturers discontinued production of this drug in 2019 due to business considerations and concern for profit margins.&#x000a0;</p>
          </list-item>
        </list>
        <p><bold>Xanthine oxidase inhibitors</bold> block the hepatic oxidation of xanthine to uric acid.<xref ref-type="bibr" rid="article-23243.r71">[71]</xref>&#x000a0;Xanthine does not cause gout, is non-toxic until very high concentrations, and is much more soluble in urine than uric acid.<xref ref-type="bibr" rid="article-23243.r71">[71]</xref>&#x000a0;See our companion StatPearls reference article on "Biochemistry, Xanthine Oxidase."<xref ref-type="bibr" rid="article-23243.r72">[72]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p><bold>&#x000a0;Allopurinol</bold>&#x000a0;is a purine-based structural analog of hypoxanthine that acts as a xanthine oxidase inhibitor.<xref ref-type="bibr" rid="article-23243.r73">[73]</xref> It is the preferred agent for patients with symptomatic hyperuricemia, gout, and hyperuricosuric nephrolithiasis.<xref ref-type="bibr" rid="article-23243.r71">[71]</xref> It is also used as prophylaxis against gouty arthritis and chemotherapy-related hyperuricemia. It is effective and inexpensive, but treatment usually is lifelong.&#x000a0;Compared to febuxostat, allopurinol appears to offer superior renal protection.<xref ref-type="bibr" rid="article-23243.r74">[74]</xref>&#x000a0;For tumor lysis syndrome prophylaxis, allopurinol should be started two or three days before initiating chemotherapy and continued for up to a week after the chemotherapy course.<xref ref-type="bibr" rid="article-23243.r71">[71]</xref>&#x000a0;See our companion StatPearls reference article on "Allopurinol."<xref ref-type="bibr" rid="article-23243.r71">[71]</xref>&#x000a0;The overall use of allopurinol is suboptimal, as many patients with gout either do not receive long-term treatment or are&#x000a0;significantly underdosed.<xref ref-type="bibr" rid="article-23243.r75">[75]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Allergic reactions to allopurinol have been reported in up to 25% of patients. Such reactions include rashes, itching, hives, and blistering skin.<xref ref-type="bibr" rid="article-23243.r76">[76]</xref><xref ref-type="bibr" rid="article-23243.r77">[77]</xref>&#x000a0;Allopurinol hypersensitivity syndrome, a much more severe allergic reaction, presents with Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, exfoliative dermatitis, renal failure, hepatic injury, and eosinophilia.<xref ref-type="bibr" rid="article-23243.r78">[78]</xref>&#x000a0;The risk is 1:1,000 patients, and the reported mortality is 20% to 25%.<xref ref-type="bibr" rid="article-23243.r59">[59]</xref>&#x000a0;Individuals of Han Chinese, Thai, and Korean ethnicity and African Americans have a much greater risk of a specific genetic predisposition (<italic toggle="yes">HLA-B*58:01</italic>&#x000a0;allele) for this hypersensitivity response.<xref ref-type="bibr" rid="article-23243.r79">[79]</xref>&#x000a0;Genetic testing for <italic toggle="yes">HLA-B*58:01&#x000a0;</italic>should be considered for individuals of these ethnic groups before starting allopurinol therapy.<xref ref-type="bibr" rid="article-23243.r79">[79]</xref>&#x000a0; Patients&#x000a0;with pre-existing renal failure are also at higher risk of developing allopurinol hypersensitivity syndrome.<xref ref-type="bibr" rid="article-23243.r78">[78]</xref><xref ref-type="bibr" rid="article-23243.r80">[80]</xref>&#x000a0;This can be minimized by starting patients on a very low dose of &#x0003c;50 mg (&#x0003c;1.5 mg per mL/min of creatinine clearance) and titrating it upwards very gradually (such as every two to four weeks).<xref ref-type="bibr" rid="article-23243.r80">[80]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>&#x000a0;Febuxostat</bold> is a non-purine-based xanthine oxidase inhibitor primarily used for patients who fail or cannot tolerate allopurinol. At standard dosages, febuxostat appears to have superior uric acid lowering ability than allopurinol and can be used in patients with a creatinine clearance as low as 15 mL/min.<xref ref-type="bibr" rid="article-23243.r81">[81]</xref>&#x000a0;However, compared to allopurinol, patients on febuxostat demonstrated a 34% higher risk of cardiovascular mortality and 22% higher overall mortality, prompting the FDA to issue a limited-use recommendation in 2019.<xref ref-type="bibr" rid="article-23243.r82">[82]</xref>&#x000a0;See our companion StatPearls reference article on "Febuxostat."<xref ref-type="bibr" rid="article-23243.r83">[83]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Topiroxostat&#x000a0;</bold>is a xanthine oxidase inhibitor that, unlike allopurinol and febuxostat, is a non-purine agent. It is currently only approved for use in Japan. Unlike allopurinol, topiroxostat is unaffected by renal failure and can be used effectively in patients with chronic kidney disease. It was first approved for use in Japan in 2013. A post-marketing study of almost 4,500 patients over 5 years demonstrated efficacy and safety with no significant adverse drug reactions.<xref ref-type="bibr" rid="article-23243.r84">[84]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p><bold>Recombinant uricase drugs</bold> are intended for chronic gout inadequately controlled by xanthine oxidase inhibitors or uricosuric agents alone. It is estimated that about 2% of all patients with gout may be refractory to standard therapy.<xref ref-type="bibr" rid="article-23243.r85">[85]</xref> Such patients either have intractable hyperuricemia, two or more gout attacks while on therapy, or persistent subcutaneous tophi unresponsive to maximum dosages of conventional therapy.<xref ref-type="bibr" rid="article-23243.r86">[86]</xref>&#x000a0;</p>
        <p>Uricase drugs work by enzymatically converting&#x000a0;uric acid to the water-soluble, non-toxic, purine metabolite allantoin, which is then readily excreted by the kidneys.<xref ref-type="bibr" rid="article-23243.r87">[87]</xref>&#x000a0;Other than humans and higher primates, most mammals naturally produce uricase and have much lower normal uric acid. Recombinant uricase drugs do not interfere with uric acid production or change its excretion. They are very effective in lowering uric acid in serum and urine.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>&#x000a0;Rasburicase</bold>&#x000a0;was the first recombinant uricase to treat significant hyperuricemia from tumor lysis syndrome.<xref ref-type="bibr" rid="article-23243.r36">[36]</xref> It was FDA-approved in 2002 for temporarily managing hyperuricemia in cancer patients with leukemia, lymphoma, and solid malignant lesions receiving chemotherapy likely to cause tumor lysis syndrome that would otherwise cause extremely high serum uric acid levels.<xref ref-type="bibr" rid="article-23243.r36">[36]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>It works quickly (within 4 hours). It effectively controls uric acid levels in tumor lysis syndrome and avoids hemodialysis. Still, it is expensive, has a short&#x000a0;half-life of 16 to 21 hours, and promotes the rapid development of antibodies to the drug.<xref ref-type="bibr" rid="article-23243.r88">[88]</xref><xref ref-type="bibr" rid="article-23243.r89">[89]</xref><xref ref-type="bibr" rid="article-23243.r90">[90]</xref><xref ref-type="bibr" rid="article-23243.r91">[91]</xref><xref ref-type="bibr" rid="article-23243.r92">[92]</xref><xref ref-type="bibr" rid="article-23243.r93">[93]</xref>&#x000a0;See our companion StatPearls reference article on "Tumor Lysis Syndrome."<xref ref-type="bibr" rid="article-23243.r94">[94]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Pegloticase</bold>&#x000a0;is a recombinant uricase (uric acid oxidase) that was FDA-approved in 2010 for chronic gout refractory to standard therapy.<xref ref-type="bibr" rid="article-23243.r87">[87]</xref><xref ref-type="bibr" rid="article-23243.r95">[95]</xref>&#x000a0;(Its marketing authorization was discontinued in the European Union in 2016 due to business and commercial reasons.)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>To decrease immune reactivity and extend the half-life, an inert polyethylene glycol (PEG) was chemically&#x000a0;attached to the rasburicase enzyme, making it "pegylated" and leading to pegloticase.<xref ref-type="bibr" rid="article-23243.r85">[85]</xref><xref ref-type="bibr" rid="article-23243.r96">[96]</xref><xref ref-type="bibr" rid="article-23243.r97">[97]</xref><xref ref-type="bibr" rid="article-23243.r98">[98]</xref>&#x000a0;The half-life is longer than rasburicase at 8.5 days but remains highly immunogenic, requiring concomitant methotrexate as an immunosuppressive.<xref ref-type="bibr" rid="article-23243.r85">[85]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pegloticase&#x000a0;was created using a genetically altered variant of E. coli. Effectiveness was demonstrated in two multinational, six-month, randomized, double-blinded, placebo-controlled trials.<xref ref-type="bibr" rid="article-23243.r99">[99]</xref><xref ref-type="bibr" rid="article-23243.r100">[100]</xref>&#x000a0;In addition to significantly lowering serum uric acid levels, pegloticase has been shown to shrink and resolve tophi, decrease joint pain, improve swelling, and even significantly reduce blood pressure in hyperuricemic patients without affecting kidney function.<xref ref-type="bibr" rid="article-23243.r85">[85]</xref><xref ref-type="bibr" rid="article-23243.r100">[100]</xref>&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients on pegloticase can develop infusion reactions and antidrug antibodies that reduce its effectiveness.<xref ref-type="bibr" rid="article-23243.r85">[85]</xref>&#x000a0;These side effects can be eliminated by stopping the medication when it starts to lose efficacy or at the start of an adverse reaction, as well as by using immunosuppressive drugs such as methotrexate.<xref ref-type="bibr" rid="article-23243.r85">[85]</xref><xref ref-type="bibr" rid="article-23243.r101">[101]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The combination of pegloticase with methotrexate showed markedly increased response over pegloticase alone (71% vs. 38.5%) with similar adverse effects and much lower rates of infusion reactions and antidrug antibody production.<xref ref-type="bibr" rid="article-23243.r95">[95]</xref><xref ref-type="bibr" rid="article-23243.r101">[101]</xref><xref ref-type="bibr" rid="article-23243.r102">[102]</xref>&#x000a0;Gout flares are common (88%) when initiating pegloticase therapy.<xref ref-type="bibr" rid="article-23243.r100">[100]</xref>&#x000a0;Pegloticase is costly, and anaphylaxis has been reported.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Folic acid supplementation should be started at least four weeks before beginning therapy. Other uric acid-lowering medications should be discontinued before starting pegloticase. Before every infusion, uric acid serum levels should be monitored, and patients should be premedicated with antihistamines and corticosteroids.<xref ref-type="bibr" rid="article-23243.r95">[95]</xref>&#x000a0;It is contraindicated in patients with glucose-6-phosphate deficiency and is not recommended for asymptomatic patients.<xref ref-type="bibr" rid="article-23243.r95">[95]</xref> See our companion StatPearls reference article on "Pegloticase."<xref ref-type="bibr" rid="article-23243.r95">[95]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Treatment Summary</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Allopurinol is the preferred initial treatment for hyperuricemia. If this is ineffective or not tolerated, then febuxostat is recommended. Dosage is adjusted until optimal serum (&#x0003c;6 mg/dL) or 24-hour urine (&#x0003c;600 mg/day) uric acid levels are achieved.<xref ref-type="bibr" rid="article-23243.r71">[71]</xref><xref ref-type="bibr" rid="article-23243.r103">[103]</xref><xref ref-type="bibr" rid="article-23243.r104">[104]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Febuxostat is recommended if allopurinol is not well tolerated, ineffective, or if there is a genetic risk of allopurinol hypersensitivity syndrome.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In uric acid urolithiasis, treatment primarily reduces urinary acidity (to pH &#x0003e;6.5) with potassium citrate or sodium bicarbonate rather than just reducing hyperuricosuria.<xref ref-type="bibr" rid="article-23243.r103">[103]</xref> Increasing urinary volume is also recommended. See our companion StatPearls reference article on "Uric Acid Nephrolithiasis" and "Hyperuricosuria."<xref ref-type="bibr" rid="article-23243.r103">[103]</xref><xref ref-type="bibr" rid="article-23243.r105">[105]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In hyperuricosuric calcium nephrolithiasis, treatment is focused on optimizing urinary citrate with potassium citrate (urinary citrate goal is 500-600 mg/day) and reducing uric acid urinary excretion (usually with allopurinol).<xref ref-type="bibr" rid="article-23243.r104">[104]</xref><xref ref-type="bibr" rid="article-23243.r106">[106]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Probenecid with or without colchicine can be used for gout prophylaxis but is not recommended for patients with uric acid nephrolithiasis or hyperuricosuria (&#x0003e;800 mg urinary uric acid/24 hours).</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pegloticase can be used for otherwise intractable, symptomatic hyperuricemia in patients with ineffective or intolerable alternative treatments.<xref ref-type="bibr" rid="article-23243.r95">[95]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Rasburicase is recommended for temporary use in acute hyperuricemia due to tumor lysis syndrome but not for gout.<xref ref-type="bibr" rid="article-23243.r36">[36]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23243.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Hyperuricemia alone does not cause clinical symptoms. However, other conditions can cause the symptoms of gout or nephrolithiasis often seen with elevated uric acid. Some of these conditions are rheumatoid arthritis, pseudogout (calcium pyrophosphate deposition disease), arthritis, hypothyroidism, alcoholic ketoacidosis, non-urate-based nephrolithiasis, hemolytic anemia, hyperparathyroidism, and malignancies.</p>
      </sec>
      <sec id="article-23243.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Most patients with hyperuricemia are asymptomatic. Patients can be easily treated with several medication classes if they develop symptoms. There is evidence that hyperuricemia is a precursor to the development of hypertension, metabolic disease, diabetes, and cardiovascular and renal disease, but a definitive causal link has not been established. Urate-lowering therapy for asymptomatic patients is not yet standard.</p>
      </sec>
      <sec id="article-23243.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Hyperuricemia primarily is known to have complications related to nephrolithiasis and gout. Some of the potential side effects include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Bone loss</p>
          </list-item>
          <list-item>
            <p>Chronic kidney disease&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Gout</p>
          </list-item>
          <list-item>
            <p>Hypertension</p>
          </list-item>
          <list-item>
            <p>Joint damage and&#x000a0;deformity</p>
          </list-item>
          <list-item>
            <p>Tophi deposits</p>
          </list-item>
          <list-item>
            <p>Loss of mobility</p>
          </list-item>
          <list-item>
            <p>Nephrolithiasis (uric acid and calcium oxalate)</p>
          </list-item>
          <list-item>
            <p>Restricted range of motion</p>
          </list-item>
          <list-item>
            <p>Skin rashes</p>
          </list-item>
          <list-item>
            <p>Allopurinol sensitivity syndrome</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23243.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients with symptomatic hyperuricemia (gout, uric acid stones, or hyperuricosuric calcium nephrolithiasis) should be on prophylactic treatment, usually starting with allopurinol. Patients at risk for a flare, especially those with renal failure, should be started on a low dose of uric acid-lowering agents and gradually titrated upwards.<xref ref-type="bibr" rid="article-23243.r80">[80]</xref>&#x000a0;Dietary education should be prioritized regarding a low-purine, low-salt, and low-fructose diet. Many patients will benefit from seeing a dietician regularly.</p>
      </sec>
      <sec id="article-23243.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Key facts regarding hyperuricemia are listed below.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Most patients with gout are not on optimal doses of their uric acid-lowering medications.<xref ref-type="bibr" rid="article-23243.r75">[75]</xref>&#x000a0; Many patients will need higher doses than the typical 300 mg daily to achieve optimal serum levels of 6 mg/dL or less.<xref ref-type="bibr" rid="article-23243.r75">[75]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Allopurinol hypersensitivity syndrome is a rare but potentially fatal reaction.<xref ref-type="bibr" rid="article-23243.r59">[59]</xref>&#x000a0;African Americans and individuals of Chinese, Korean, and Thai ancestry should be tested for the&#x000a0;<italic toggle="yes">HLA-B*58:01</italic>&#x000a0;allele, which predisposes them to this dangerous hypersensitivity reaction, before starting allopurinol therapy.<xref ref-type="bibr" rid="article-23243.r79">[79]</xref>&#x000a0;Allopurinol should be avoided in those who test positive for this gene.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients with chronic kidney disease are also at higher risk.<xref ref-type="bibr" rid="article-23243.r78">[78]</xref><xref ref-type="bibr" rid="article-23243.r80">[80]</xref>&#x000a0;In these patients, use low doses of allopurinol initially and gradually titrate upwards only every 2-4 weeks.<xref ref-type="bibr" rid="article-23243.r80">[80]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pegloticase should generally only be used with methotrexate.<xref ref-type="bibr" rid="article-23243.r95">[95]</xref>&#x000a0;Stop all other uric acid-lowering drugs and start folic acid supplementation.<xref ref-type="bibr" rid="article-23243.r95">[95]</xref> At every infusion, patients should be premedicated with steroids and antihistamines.<xref ref-type="bibr" rid="article-23243.r95">[95]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In patients with chronic kidney disease, xanthine oxidase inhibitors are generally preferred, but possibly at a lower starting dose.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Among uricosuric agents, only benzbromarone&#x000a0; (not available in the United States and Europe)can be used in patients with significant chronic kidney disease.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients with diuretic-induced hyperuricemia and gout can be treated with losartan or allopurinol but do not need any therapy if they are asymptomatic.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23243.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Because there are many causes of hyperuricemia, the condition is best managed by an interprofessional team that may include internists, primary care providers, endocrinologists, urologists, rheumatologists, and oncologists. Most patients are asymptomatic and do not need medical therapy for hyperuricemia.</p>
        <p>The cost of unnecessary drugs and the potential for adverse effects outweigh the benefit of starting medication for most asymptomatic patients with hyperuricemia.&#x000a0;Uric acid-lowering&#x000a0;medications in such patients are only indicated in those undergoing cytolytic therapy for malignancy to prevent tumor lysis syndrome.<xref ref-type="bibr" rid="article-23243.r107">[107]</xref><xref ref-type="bibr" rid="article-23243.r108">[108]</xref></p>
        <p>The outlook for benign causes of hyperuricemia is good, but those with malignancy may develop complications like gout or renal&#x000a0;</p>
      </sec>
      <sec id="article-23243.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23243&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23243">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/hormones-and-body-chemistry/hyperuricemia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=23243">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23243/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23243">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23243.s17">
        <title>References</title>
        <ref id="article-23243.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yip</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Pillinger</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Asymptomatic hyperuricemia: is it really asymptomatic?</article-title>
            <source>Curr Opin Rheumatol</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>71</fpage>
            <page-range>71-79</page-range>
            <pub-id pub-id-type="pmid">31688126</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barkas</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Elisaf</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liberopoulos</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kalaitzidis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Liamis</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Uric acid and incident chronic kidney disease in dyslipidemic individuals.</article-title>
            <source>Curr Med Res Opin</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>34</volume>
            <issue>7</issue>
            <fpage>1193</fpage>
            <page-range>1193-1199</page-range>
            <pub-id pub-id-type="pmid">28836857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Song</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>A brief review of urate transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: Current therapeutic options and potential applications.</article-title>
            <source>Eur J Pharmacol</source>
            <year>2021</year>
            <month>Sep</month>
            <day>15</day>
            <volume>907</volume>
            <fpage>174291</fpage>
            <pub-id pub-id-type="pmid">34216576</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhole</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>de Vera</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Serum uric acid levels and the risk of type 2 diabetes: a prospective study.</article-title>
            <source>Am J Med</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>123</volume>
            <issue>10</issue>
            <fpage>957</fpage>
            <page-range>957-61</page-range>
            <pub-id pub-id-type="pmid">20920699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Borghi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rosei</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Bardin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dominiczak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kielstein</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Manolis</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Perez-Ruiz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mancia</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Serum uric acid and the risk of cardiovascular and renal disease.</article-title>
            <source>J Hypertens</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>33</volume>
            <issue>9</issue>
            <fpage>1729</fpage>
            <page-range>1729-41; discussion 1741</page-range>
            <pub-id pub-id-type="pmid">26136207</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Borghi</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The role of uric acid in the development of cardiovascular disease.</article-title>
            <source>Curr Med Res Opin</source>
            <year>2015</year>
            <volume>31 Suppl 2</volume>
            <fpage>1</fpage>
            <page-range>1-2</page-range>
            <pub-id pub-id-type="pmid">26414729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanchez-Lozada</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Andres-Hernando</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garcia-Arroyo</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Cicerchi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kuwabara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Roncal-Jimenez</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Lanaspa</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Uric acid activates aldose reductase and the polyol pathway for endogenous fructose and fat production causing development of fatty liver in rats.</article-title>
            <source>J Biol Chem</source>
            <year>2019</year>
            <month>Mar</month>
            <day>15</day>
            <volume>294</volume>
            <issue>11</issue>
            <fpage>4272</fpage>
            <page-range>4272-4281</page-range>
            <pub-id pub-id-type="pmid">30651350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Russo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Leoncini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Esposito</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Garibotto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pontremoli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Viazzi</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Fructose and Uric Acid: Major Mediators of Cardiovascular Disease Risk Starting at Pediatric Age.</article-title>
            <source>Int J Mol Sci</source>
            <year>2020</year>
            <month>Jun</month>
            <day>24</day>
            <volume>21</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">32599713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dong</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Visceral adiposity index is strongly associated with hyperuricemia independently of metabolic health and obesity phenotypes.</article-title>
            <source>Sci Rep</source>
            <year>2017</year>
            <month>Aug</month>
            <day>18</day>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>8822</fpage>
            <pub-id pub-id-type="pmid">28821853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kahn</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Effect of diuretics on the renal handling of urate.</article-title>
            <source>Semin Nephrol</source>
            <year>1988</year>
            <month>Sep</month>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>305</fpage>
            <page-range>305-14</page-range>
            <pub-id pub-id-type="pmid">3059433</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carlsen</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>K&#x000f8;ber</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Torp-Pedersen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Johansen</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects.</article-title>
            <source>BMJ</source>
            <year>1990</year>
            <month>Apr</month>
            <day>14</day>
            <volume>300</volume>
            <issue>6730</issue>
            <fpage>975</fpage>
            <page-range>975-8</page-range>
            <pub-id pub-id-type="pmid">2344503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hagos</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ugele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Burckhardt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bahn</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Human renal organic anion transporter 4 operates as an asymmetric urate transporter.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>430</fpage>
            <page-range>430-9</page-range>
            <pub-id pub-id-type="pmid">17229912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weinman</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Eknoyan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Suki</surname>
                <given-names>WN</given-names>
              </name>
            </person-group>
            <article-title>The influence of the extracellular fluid volume on the tubular reabsorption of uric acid.</article-title>
            <source>J Clin Invest</source>
            <year>1975</year>
            <month>Feb</month>
            <volume>55</volume>
            <issue>2</issue>
            <fpage>283</fpage>
            <page-range>283-91</page-range>
            <pub-id pub-id-type="pmid">1127100</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steele</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Oppenheimer</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Factors affecting urate excretion following diuretic administration in man.</article-title>
            <source>Am J Med</source>
            <year>1969</year>
            <month>Oct</month>
            <volume>47</volume>
            <issue>4</issue>
            <fpage>564</fpage>
            <page-range>564-74</page-range>
            <pub-id pub-id-type="pmid">4309843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Atkinson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Karlson</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Curhan</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study.</article-title>
            <source>Arch Intern Med</source>
            <year>2005</year>
            <month>Apr</month>
            <day>11</day>
            <volume>165</volume>
            <issue>7</issue>
            <fpage>742</fpage>
            <page-range>742-8</page-range>
            <pub-id pub-id-type="pmid">15824292</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>W&#x000fc;rzner</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gerster</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Chiolero</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maillard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fallab-Stubi</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Brunner</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Burnier</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.</article-title>
            <source>J Hypertens</source>
            <year>2001</year>
            <month>Oct</month>
            <volume>19</volume>
            <issue>10</issue>
            <fpage>1855</fpage>
            <page-range>1855-60</page-range>
            <pub-id pub-id-type="pmid">11593107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weinberger</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Influence of an angiotensin converting-enzyme inhibitor on diuretic-induced metabolic effects in hypertension.</article-title>
            <source>Hypertension</source>
            <year>1983</year>
            <season>Sep-Oct</season>
            <volume>5</volume>
            <issue>5 Pt 2</issue>
            <fpage>III132</fpage>
            <page-range>III132-8</page-range>
            <pub-id pub-id-type="pmid">6313523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shahinfar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Carides</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Thiyagarajan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nakagawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Umans</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Parks</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Coe</surname>
                <given-names>FL</given-names>
              </name>
            </person-group>
            <article-title>Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia.</article-title>
            <source>Kidney Int</source>
            <year>1999</year>
            <month>Nov</month>
            <volume>56</volume>
            <issue>5</issue>
            <fpage>1879</fpage>
            <page-range>1879-85</page-range>
            <pub-id pub-id-type="pmid">10571797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soffer</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Pratt</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Wiens</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Sweet</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Effects of losartan on a background of hydrochlorothiazide in patients with hypertension.</article-title>
            <source>Hypertension</source>
            <year>1995</year>
            <month>Jul</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>112</fpage>
            <page-range>112-7</page-range>
            <pub-id pub-id-type="pmid">7607713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manolis</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jelakovic</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jacovides</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bernhardi</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Cabrera</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Barragan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Matadamas</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mendiola</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Mejia</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Bunt</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dumortier</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators.</article-title>
            <source>Clin Ther</source>
            <year>2000</year>
            <month>Oct</month>
            <volume>22</volume>
            <issue>10</issue>
            <fpage>1186</fpage>
            <page-range>1186-203</page-range>
            <pub-id pub-id-type="pmid">11110230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tikkanen</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Omvik</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension.</article-title>
            <source>J Hypertens</source>
            <year>1995</year>
            <month>Nov</month>
            <volume>13</volume>
            <issue>11</issue>
            <fpage>1343</fpage>
            <page-range>1343-51</page-range>
            <pub-id pub-id-type="pmid">8984133</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buscemi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Buscemi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Borz&#x000ec;</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Cosentino</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rosafio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Randazzo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Colomba</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Di Raimondo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pluchinotta</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Parrinello</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Metabolic and Cardiovascular Effects of Switching Thiazides to Amlodipine in Hypertensive Patients With and Without Type 2 Diabetes (the Diuretics and Diabetes Control Study).</article-title>
            <source>Metab Syndr Relat Disord</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>110</fpage>
            <page-range>110-118</page-range>
            <pub-id pub-id-type="pmid">31976814</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Update on the epidemiology, genetics, and therapeutic options of hyperuricemia.</article-title>
            <source>Am J Transl Res</source>
            <year>2020</year>
            <volume>12</volume>
            <issue>7</issue>
            <fpage>3167</fpage>
            <page-range>3167-3181</page-range>
            <pub-id pub-id-type="pmid">32774692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>The History, Symptoms, Causes, Risk Factors, Types, Diagnosis, Treatments, and Prevention of Gout, Part 2.</article-title>
            <source>Int J Pharm Compd</source>
            <year>2019</year>
            <season>Jan-Feb</season>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>14</fpage>
            <page-range>14-21</page-range>
            <pub-id pub-id-type="pmid">30668531</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campion</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Glynn</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>DeLabry</surname>
                <given-names>LO</given-names>
              </name>
            </person-group>
            <article-title>Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study.</article-title>
            <source>Am J Med</source>
            <year>1987</year>
            <month>Mar</month>
            <volume>82</volume>
            <issue>3</issue>
            <fpage>421</fpage>
            <page-range>421-6</page-range>
            <pub-id pub-id-type="pmid">3826098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lingala</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mithal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Gout and hyperuricaemia in the USA: prevalence and trends.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2019</year>
            <month>Dec</month>
            <day>01</day>
            <volume>58</volume>
            <issue>12</issue>
            <fpage>2177</fpage>
            <page-range>2177-2180</page-range>
            <pub-id pub-id-type="pmid">31168609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gosling</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Matisoo-Smith</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Merriman</surname>
                <given-names>TR</given-names>
              </name>
            </person-group>
            <article-title>Hyperuricaemia in the Pacific: why the elevated serum urate levels?</article-title>
            <source>Rheumatol Int</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>34</volume>
            <issue>6</issue>
            <fpage>743</fpage>
            <page-range>743-57</page-range>
            <pub-id pub-id-type="pmid">24378761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>You</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The biomarkers discovery of hyperuricemia and gout: proteomics and metabolomics.</article-title>
            <source>PeerJ</source>
            <year>2023</year>
            <volume>11</volume>
            <fpage>e14554</fpage>
            <pub-id pub-id-type="pmid">36632144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yokokawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fukuda</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fujibayashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Naito</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Uehara</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nakayama</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Matsuo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sanada</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jose</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Miwa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hisaoka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Isonuma</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Association Between Serum Uric Acid Levels/Hyperuricemia and Hypertension Among 85,286 Japanese Workers.</article-title>
            <source>J Clin Hypertens (Greenwich)</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>53</fpage>
            <page-range>53-9</page-range>
            <pub-id pub-id-type="pmid">26212524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paquot</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Scheen</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>[DPP-4 or SGLT2 inhibitor added to metformin alone in type 2 diabetes].</article-title>
            <source>Rev Med Suisse</source>
            <year>2017</year>
            <month>Aug</month>
            <day>23</day>
            <volume>13</volume>
            <issue>571</issue>
            <fpage>1410</fpage>
            <page-range>1410-1415</page-range>
            <pub-id pub-id-type="pmid">28837277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Does obesity modify the epidemiological association between hyperuricemia and the prevalence of hypertension among Northern Chinese community-dwelling people? A Chinese population-based study.</article-title>
            <source>BMJ Open</source>
            <year>2019</year>
            <month>Nov</month>
            <day>21</day>
            <volume>9</volume>
            <issue>11</issue>
            <fpage>e031803</fpage>
            <pub-id pub-id-type="pmid">31753884</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Borghi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Agabiti-Rosei</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kielstein</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Lurbe</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mancia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Redon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stack</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Tsioufis</surname>
                <given-names>KP</given-names>
              </name>
            </person-group>
            <article-title>Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease.</article-title>
            <source>Eur J Intern Med</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>80</volume>
            <fpage>1</fpage>
            <page-range>1-11</page-range>
            <pub-id pub-id-type="pmid">32739239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ejaz</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Shimada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mohandas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Alquadan</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Beaver</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Lapsia</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dass</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>The Role of Uric Acid in Acute Kidney Injury.</article-title>
            <source>Nephron</source>
            <year>2019</year>
            <volume>142</volume>
            <issue>4</issue>
            <fpage>275</fpage>
            <page-range>275-283</page-range>
            <pub-id pub-id-type="pmid">30991383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hassan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Shrestha</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sumida</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sweeney</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Potukuchi</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Rhee</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Streja</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kalantar-Zadeh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kovesdy</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Association of Uric Acid-Lowering Therapy With Incident Chronic Kidney Disease.</article-title>
            <source>JAMA Netw Open</source>
            <year>2022</year>
            <month>Jun</month>
            <day>01</day>
            <volume>5</volume>
            <issue>6</issue>
            <fpage>e2215878</fpage>
            <pub-id pub-id-type="pmid">35657621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rincon-Choles</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jolly</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Arrigain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Konig</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Schold</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Nakhoul</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Navaneethan</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Nally</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Rothberg</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Impact of Uric Acid Levels on Kidney Disease Progression.</article-title>
            <source>Am J Nephrol</source>
            <year>2017</year>
            <volume>46</volume>
            <issue>4</issue>
            <fpage>315</fpage>
            <page-range>315-322</page-range>
            <pub-id pub-id-type="pmid">29032376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yakupova</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Gout. New opportunities of diagnosis and treatment.</article-title>
            <source>Ter Arkh</source>
            <year>2018</year>
            <month>May</month>
            <day>11</day>
            <volume>90</volume>
            <issue>5</issue>
            <fpage>88</fpage>
            <page-range>88-92</page-range>
            <pub-id pub-id-type="pmid">30701896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shiraishi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Une</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The effect of the interaction between obesity and drinking on hyperuricemia in Japanese male office workers.</article-title>
            <source>J Epidemiol</source>
            <year>2009</year>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>12</fpage>
            <page-range>12-6</page-range>
            <pub-id pub-id-type="pmid">19164873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r38">
          <label>38</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>de Brouwer</surname>
                <given-names>APM</given-names>
              </name>
              <name>
                <surname>Christodoulou</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <chapter-title>Phosphoribosylpyrophosphate Synthetase Superactivity</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2008</year>
            <month>9</month>
            <day>23</day>
            <pub-id pub-id-type="pmid">20301734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dewulf</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Marie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nassogne</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Disorders of purine biosynthesis metabolism.</article-title>
            <source>Mol Genet Metab</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>136</volume>
            <issue>3</issue>
            <fpage>190</fpage>
            <page-range>190-198</page-range>
            <pub-id pub-id-type="pmid">34998670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gosling</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Gaffo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abhishek</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Gout.</article-title>
            <source>Lancet</source>
            <year>2021</year>
            <month>May</month>
            <day>15</day>
            <volume>397</volume>
            <issue>10287</issue>
            <fpage>1843</fpage>
            <page-range>1843-1855</page-range>
            <pub-id pub-id-type="pmid">33798500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Kuang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Discovery of novel benzbromarone analogs with improved pharmacokinetics and benign toxicity profiles as antihyperuricemic agents.</article-title>
            <source>Eur J Med Chem</source>
            <year>2022</year>
            <month>Nov</month>
            <day>15</day>
            <volume>242</volume>
            <fpage>114682</fpage>
            <pub-id pub-id-type="pmid">36001935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bobulescu</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Moe</surname>
                <given-names>OW</given-names>
              </name>
            </person-group>
            <article-title>Renal transport of uric acid: evolving concepts and uncertainties.</article-title>
            <source>Adv Chronic Kidney Dis</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>358</fpage>
            <page-range>358-71</page-range>
            <pub-id pub-id-type="pmid">23089270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r43">
          <label>43</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Fenando</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rednam</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gujarathi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Widrich</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <chapter-title>Gout</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">31536213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r44">
          <label>44</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Patti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <chapter-title>Acute Renal Colic</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>6</month>
            <day>6</day>
            <pub-id pub-id-type="pmid">28613743</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Estill</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Qian</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Reporting, presentation and wording of recommendations in clinical practice guideline for gout: a systematic analysis.</article-title>
            <source>BMJ Open</source>
            <year>2019</year>
            <month>Jan</month>
            <day>29</day>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>e024315</fpage>
            <pub-id pub-id-type="pmid">30700479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alqarni</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Hassan</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>Knowledge and practice in the management of asymptomatic hyperuricemia among primary health care physicians in Jeddah, Western Region of Saudi Arabia.</article-title>
            <source>Saudi Med J</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>39</volume>
            <issue>12</issue>
            <fpage>1218</fpage>
            <page-range>1218-1225</page-range>
            <pub-id pub-id-type="pmid">30520504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Engel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schacher</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weckbecker</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stausberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gr&#x000e4;ff</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>[Acute Gout in Emergency Admissions - Patient Characteristics and Adherence of Care Processes to Current Guidelines].</article-title>
            <source>Z Orthop Unfall</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>156</volume>
            <issue>6</issue>
            <fpage>653</fpage>
            <page-range>653-661</page-range>
            <pub-id pub-id-type="pmid">29986356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buzas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tautu</surname>
                <given-names>OF</given-names>
              </name>
              <name>
                <surname>Dorobantu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ivan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lighezan</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Serum uric acid and arterial hypertension-Data from Sephar III survey.</article-title>
            <source>PLoS One</source>
            <year>2018</year>
            <volume>13</volume>
            <issue>7</issue>
            <fpage>e0199865</fpage>
            <pub-id pub-id-type="pmid">29966019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>FitzGerald</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mikuls</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Brignardello-Petersen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Guyatt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Abeles</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Gelber</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Harrold</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Libbey</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mount</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pillinger</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Rosenthal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Sims</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Wenger</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Danve</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Lenert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Poon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Qasim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sehra</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>TSK</given-names>
              </name>
              <name>
                <surname>Toprover</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Turgunbaev</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Neogi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>2020 American College of Rheumatology Guideline for the Management of Gout.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>72</volume>
            <issue>6</issue>
            <fpage>879</fpage>
            <page-range>879-895</page-range>
            <pub-id pub-id-type="pmid">32390306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r50">
          <label>50</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Sadiq</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Terrell</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <chapter-title>Colchicine</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>29</day>
            <pub-id pub-id-type="pmid">28613754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Terkeltaub</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Clinical practice. Gout.</article-title>
            <source>N Engl J Med</source>
            <year>2003</year>
            <month>Oct</month>
            <day>23</day>
            <volume>349</volume>
            <issue>17</issue>
            <fpage>1647</fpage>
            <page-range>1647-55</page-range>
            <pub-id pub-id-type="pmid">14573737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leung</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Yao Hui</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Kraus</surname>
                <given-names>VB</given-names>
              </name>
            </person-group>
            <article-title>Colchicine--Update on mechanisms of action and therapeutic uses.</article-title>
            <source>Semin Arthritis Rheum</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>341</fpage>
            <page-range>341-50</page-range>
            <pub-id pub-id-type="pmid">26228647</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doherty</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sarmanova</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abhishek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ashton</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Barclay</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Doherty</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Duley</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hatton</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rees</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial.</article-title>
            <source>Lancet</source>
            <year>2018</year>
            <month>Oct</month>
            <day>20</day>
            <volume>392</volume>
            <issue>10156</issue>
            <fpage>1403</fpage>
            <page-range>1403-1412</page-range>
            <pub-id pub-id-type="pmid">30343856</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Enomoto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chairoungdua</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shigeta</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jutabha</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cha</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Hosoyamada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Takeda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sekine</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Igarashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Matsuo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kikuchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Oda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ichida</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hosoya</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shimokata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Niwa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kanai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Endou</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Molecular identification of a renal urate anion exchanger that regulates blood urate levels.</article-title>
            <source>Nature</source>
            <year>2002</year>
            <month>May</month>
            <day>23</day>
            <volume>417</volume>
            <issue>6887</issue>
            <fpage>447</fpage>
            <page-range>447-52</page-range>
            <pub-id pub-id-type="pmid">12024214</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Milionis</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Kakafika</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Tsouli</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Athyros</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Bairaktari</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Seferiadis</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Elisaf</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia.</article-title>
            <source>Am Heart J</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>148</volume>
            <issue>4</issue>
            <fpage>635</fpage>
            <page-range>635-40</page-range>
            <pub-id pub-id-type="pmid">15459594</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feher</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Hepburn</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Hogarth</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Ball</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2003</year>
            <month>Feb</month>
            <volume>42</volume>
            <issue>2</issue>
            <fpage>321</fpage>
            <page-range>321-5</page-range>
            <pub-id pub-id-type="pmid">12595630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Granados</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Bhatnagar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Nigam</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Blockade of Organic Anion Transport in Humans After Treatment With the Drug Probenecid Leads to Major Metabolic Alterations in Plasma and Urine.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>112</volume>
            <issue>3</issue>
            <fpage>653</fpage>
            <page-range>653-664</page-range>
            <pub-id pub-id-type="pmid">35490380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r58">
          <label>58</label>
          <element-citation publication-type="book">
            <chapter-title>Probenecid</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>7</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">31643913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khanna</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fitzgerald</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Neogi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pillinger</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Merill</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prakash</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaldas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gogia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Perez-Ruiz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Liot&#x000e9;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Niyyar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yarows</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Roessler</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kerr</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Furst</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Mandell</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Robbins</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wenger</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Terkeltaub</surname>
                <given-names>R</given-names>
              </name>
              <collab>American College of Rheumatology</collab>
            </person-group>
            <article-title>2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>64</volume>
            <issue>10</issue>
            <fpage>1431</fpage>
            <page-range>1431-46</page-range>
            <pub-id pub-id-type="pmid">23024028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r60">
          <label>60</label>
          <element-citation publication-type="book">
            <chapter-title>Benzbromarone</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>9</month>
            <day>5</day>
            <pub-id pub-id-type="pmid">31644041</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>RO</given-names>
              </name>
            </person-group>
            <article-title>A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?</article-title>
            <source>Drug Saf</source>
            <year>2008</year>
            <volume>31</volume>
            <issue>8</issue>
            <fpage>643</fpage>
            <page-range>643-65</page-range>
            <pub-id pub-id-type="pmid">18636784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reinders</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>van Roon</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Delsing</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Griep</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Hoekstra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van de Laar</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Brouwers</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>68</volume>
            <issue>1</issue>
            <fpage>51</fpage>
            <page-range>51-6</page-range>
            <pub-id pub-id-type="pmid">18250112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hosoya</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Furuno</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kanda</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout.</article-title>
            <source>Clin Exp Nephrol</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>24</volume>
            <issue>Suppl 1</issue>
            <fpage>71</fpage>
            <page-range>71-79</page-range>
            <pub-id pub-id-type="pmid">31970593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hosoya</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sasaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fushimi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ohashi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study.</article-title>
            <source>Clin Exp Nephrol</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>24</volume>
            <issue>Suppl 1</issue>
            <fpage>62</fpage>
            <page-range>62-70</page-range>
            <pub-id pub-id-type="pmid">31980978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iqbal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Iqbal</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Farid</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ishaque</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hasanain</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bin Arif</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Arshad Ali</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rathore</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Malik</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Dotinurad in Hyperuricemic Patients With or Without Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.</article-title>
            <source>Cureus</source>
            <year>2021</year>
            <month>Apr</month>
            <day>12</day>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>e14428</fpage>
            <pub-id pub-id-type="pmid">33996294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Omura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Miyata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kobashi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fushimi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Uda</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sasaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Iwanaga</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ohashi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Ideal pharmacokinetic profile of dotinurad as a selective urate reabsorption inhibitor.</article-title>
            <source>Drug Metab Pharmacokinet</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>313</fpage>
            <page-range>313-320</page-range>
            <pub-id pub-id-type="pmid">32327267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuriyama</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia.</article-title>
            <source>Clin Exp Nephrol</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>24</volume>
            <issue>Suppl 1</issue>
            <fpage>1</fpage>
            <page-range>1-5</page-range>
            <pub-id pub-id-type="pmid">31754883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Loh</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Tam</surname>
                <given-names>KW</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Lesinurad in Patients with Hyperuricemia Associated with Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.</article-title>
            <source>Pharmacotherapy</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>38</volume>
            <issue>11</issue>
            <fpage>1106</fpage>
            <page-range>1106-1119</page-range>
            <pub-id pub-id-type="pmid">30246299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cicero</surname>
                <given-names>AFG</given-names>
              </name>
              <name>
                <surname>Fogacci</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kuwabara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Borghi</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update.</article-title>
            <source>Medicina (Kaunas)</source>
            <year>2021</year>
            <month>Jan</month>
            <day>10</day>
            <volume>57</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">33435164</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fam</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient.</article-title>
            <source>Curr Rheumatol Rep</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-35</page-range>
            <pub-id pub-id-type="pmid">11177768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r71">
          <label>71</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Qurie</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Preuss</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Musa</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <chapter-title>Allopurinol</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">29763117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r72">
          <label>72</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Aziz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jamil</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <chapter-title>Biochemistry, Xanthine Oxidase</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">31424829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rundles</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>The development of allopurinol.</article-title>
            <source>Arch Intern Med</source>
            <year>1985</year>
            <month>Aug</month>
            <volume>145</volume>
            <issue>8</issue>
            <fpage>1492</fpage>
            <page-range>1492-503</page-range>
            <pub-id pub-id-type="pmid">3896181</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Superior effect of allopurinol compared to febuxostat on the retardation of chronic kidney disease progression.</article-title>
            <source>PLoS One</source>
            <year>2022</year>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>e0264627</fpage>
            <pub-id pub-id-type="pmid">35226683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarawate</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Brewer</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Bakst</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>Serum urate levels and gout flares: analysis from managed care data.</article-title>
            <source>J Clin Rheumatol</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>61</fpage>
            <page-range>61-5</page-range>
            <pub-id pub-id-type="pmid">16601538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singer</surname>
                <given-names>JZ</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality.</article-title>
            <source>Arthritis Rheum</source>
            <year>1986</year>
            <month>Jan</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>82</fpage>
            <page-range>82-7</page-range>
            <pub-id pub-id-type="pmid">3947418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hande</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Noone</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.</article-title>
            <source>Am J Med</source>
            <year>1984</year>
            <month>Jan</month>
            <volume>76</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-56</page-range>
            <pub-id pub-id-type="pmid">6691361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yaseen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Auguste</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zipursky</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Allopurinol hypersensitivity syndrome.</article-title>
            <source>CMAJ</source>
            <year>2023</year>
            <month>Apr</month>
            <day>03</day>
            <volume>195</volume>
            <issue>13</issue>
            <fpage>E483</fpage>
            <pub-id pub-id-type="pmid">37011932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quach</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Galen</surname>
                <given-names>BT</given-names>
              </name>
            </person-group>
            <article-title>HLA-B*5801 Testing to Prevent Allopurinol Hypersensitivity Syndrome: A Teachable Moment.</article-title>
            <source>JAMA Intern Med</source>
            <year>2018</year>
            <month>Sep</month>
            <day>01</day>
            <volume>178</volume>
            <issue>9</issue>
            <fpage>1260</fpage>
            <page-range>1260-1261</page-range>
            <pub-id pub-id-type="pmid">30083702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stamp</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Dockerty</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Drake</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Frampton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.</article-title>
            <source>Arthritis Rheum</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>64</volume>
            <issue>8</issue>
            <fpage>2529</fpage>
            <page-range>2529-36</page-range>
            <pub-id pub-id-type="pmid">22488501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Becker</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Wortmann</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Eustace</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Palo</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Streit</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Joseph-Ridge</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Febuxostat compared with allopurinol in patients with hyperuricemia and gout.</article-title>
            <source>N Engl J Med</source>
            <year>2005</year>
            <month>Dec</month>
            <day>08</day>
            <volume>353</volume>
            <issue>23</issue>
            <fpage>2450</fpage>
            <page-range>2450-61</page-range>
            <pub-id pub-id-type="pmid">16339094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>White</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Saag</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Borer</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Gorelick</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Whelton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Castillo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gunawardhana</surname>
                <given-names>L</given-names>
              </name>
              <collab>CARES Investigators</collab>
            </person-group>
            <article-title>Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Mar</month>
            <day>29</day>
            <volume>378</volume>
            <issue>13</issue>
            <fpage>1200</fpage>
            <page-range>1200-1210</page-range>
            <pub-id pub-id-type="pmid">29527974</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r83">
          <label>83</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Gerriets</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jialal</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <chapter-title>Febuxostat</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>5</month>
            <day>2</day>
            <pub-id pub-id-type="pmid">31334959</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ishikawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Maeda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakagawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ichikawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kanno</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study.</article-title>
            <source>Clin Drug Investig</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>40</volume>
            <issue>9</issue>
            <fpage>847</fpage>
            <page-range>847-859</page-range>
            <pub-id pub-id-type="pmid">32621143</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schlesinger</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lipsky</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Pegloticase treatment of chronic refractory gout: Update on efficacy and safety.</article-title>
            <source>Semin Arthritis Rheum</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>50</volume>
            <issue>3S</issue>
            <fpage>S31</fpage>
            <page-range>S31-S38</page-range>
            <pub-id pub-id-type="pmid">32620200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richette</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Doherty</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pascual</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Barskova</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Becce</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Casta&#x000f1;eda-Sanabria</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Coyfish</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guillo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Janssens</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liot&#x000e9;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mallen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nuki</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Perez-Ruiz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pimentao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Punzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pywell</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>So</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tausche</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Uhlig</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zavada</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Tubach</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bardin</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>2016 updated EULAR evidence-based recommendations for the management of gout.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>76</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-42</page-range>
            <pub-id pub-id-type="pmid">27457514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schlesinger</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yasothan</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kirkpatrick</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Pegloticase.</article-title>
            <source>Nat Rev Drug Discov</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-8</page-range>
            <pub-id pub-id-type="pmid">21193861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cammalleri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Malaguarnera</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.</article-title>
            <source>Int J Med Sci</source>
            <year>2007</year>
            <month>Mar</month>
            <day>02</day>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>83</fpage>
            <page-range>83-93</page-range>
            <pub-id pub-id-type="pmid">17396159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ueng</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Rasburicase (Elitek): a novel agent for tumor lysis syndrome.</article-title>
            <source>Proc (Bayl Univ Med Cent)</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>275</fpage>
            <page-range>275-9</page-range>
            <pub-id pub-id-type="pmid">16200184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davidson</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Thakkar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hix</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Bhandarkar</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schreiber</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome.</article-title>
            <source>Am J Med</source>
            <year>2004</year>
            <month>Apr</month>
            <day>15</day>
            <volume>116</volume>
            <issue>8</issue>
            <fpage>546</fpage>
            <page-range>546-54</page-range>
            <pub-id pub-id-type="pmid">15063817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pui</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Mahmoud</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Wiley</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Leverger</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Camitta</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hastings</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Blaney</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Relling</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Reaman</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma.</article-title>
            <source>J Clin Oncol</source>
            <year>2001</year>
            <month>Feb</month>
            <day>01</day>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>697</fpage>
            <page-range>697-704</page-range>
            <pub-id pub-id-type="pmid">11157020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Majumdar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sengar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thorat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nayak</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bonda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bagal</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rajendra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sethi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>A phase II study to evaluate the efficacy of low-dose rasburicase (1.5mg) in adolescent and adult acute leukemia and high-grade lymphomas with tumor lysis syndrome.</article-title>
            <source>Leuk Lymphoma</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>64</volume>
            <issue>3</issue>
            <fpage>628</fpage>
            <page-range>628-638</page-range>
            <pub-id pub-id-type="pmid">36891578</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shaikh</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Marini</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Hough</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Perissinotti</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Rational use of rasburicase for the treatment and management of tumor lysis syndrome.</article-title>
            <source>J Oncol Pharm Pract</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>176</fpage>
            <page-range>176-184</page-range>
            <pub-id pub-id-type="pmid">28077046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r94">
          <label>94</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Adeyinka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bashir</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Tumor Lysis Syndrome</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>10</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">30085527</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r95">
          <label>95</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Padda</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Parmar</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Pegloticase</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">34283420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sherman</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Saifer</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Perez-Ruiz</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>PEG-uricase in the management of treatment-resistant gout and hyperuricemia.</article-title>
            <source>Adv Drug Deliv Rev</source>
            <year>2008</year>
            <month>Jan</month>
            <day>03</day>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <page-range>59-68</page-range>
            <pub-id pub-id-type="pmid">17826865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r97">
          <label>97</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sundy</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Ganson</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Scarlett</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Rehrig</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hershfield</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.</article-title>
            <source>Arthritis Rheum</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>56</volume>
            <issue>3</issue>
            <fpage>1021</fpage>
            <page-range>1021-8</page-range>
            <pub-id pub-id-type="pmid">17328081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r98">
          <label>98</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hershfield</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Ganson</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Scarlett</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Jaggers</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Sundy</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients.</article-title>
            <source>Arthritis Res Ther</source>
            <year>2014</year>
            <month>Mar</month>
            <day>07</day>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>R63</fpage>
            <pub-id pub-id-type="pmid">24602182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r99">
          <label>99</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sundy</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Baraf</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Yood</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Gutierrez-Urena</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Treadwell</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>V&#x000e1;zquez-Mellado</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Lipsky</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Horowitz</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Maroli</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Waltrip</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Hamburger</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.</article-title>
            <source>JAMA</source>
            <year>2011</year>
            <month>Aug</month>
            <day>17</day>
            <volume>306</volume>
            <issue>7</issue>
            <fpage>711</fpage>
            <page-range>711-20</page-range>
            <pub-id pub-id-type="pmid">21846852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r100">
          <label>100</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sundy</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Baraf</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Barkhuizen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moreland</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Waltrip</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Maroli</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Horowitz</surname>
                <given-names>Z</given-names>
              </name>
              <collab>Pegloticase Phase 2 Study Investigators</collab>
            </person-group>
            <article-title>Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.</article-title>
            <source>Arthritis Rheum</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>58</volume>
            <issue>9</issue>
            <fpage>2882</fpage>
            <page-range>2882-91</page-range>
            <pub-id pub-id-type="pmid">18759308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r101">
          <label>101</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Botson</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Saag</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Parikh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>La</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>LoCicero</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Obermeyer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Xin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chamberlain</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>LaMoreaux</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sainati</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grewal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Majjhoo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tesser</surname>
                <given-names>JRP</given-names>
              </name>
              <name>
                <surname>Weinblatt</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>75</volume>
            <issue>2</issue>
            <fpage>293</fpage>
            <page-range>293-304</page-range>
            <pub-id pub-id-type="pmid">36099211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r102">
          <label>102</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Botson</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Obermeyer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>LaMoreaux</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Weinblatt</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial.</article-title>
            <source>Arthritis Res Ther</source>
            <year>2022</year>
            <month>Dec</month>
            <day>27</day>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>281</fpage>
            <pub-id pub-id-type="pmid">36575505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r103">
          <label>103</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>KC</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <chapter-title>Uric Acid Nephrolithiasis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>10</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">32809561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r104">
          <label>104</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Sajjad</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bashir</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>24-Hour Urine Testing for Nephrolithiasis: Interpretation and Treatment Guidelines</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>4</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">29494055</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r105">
          <label>105</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Kaur</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <chapter-title>Hyperuricosuria</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">32965872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r106">
          <label>106</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yu</surname>
                <given-names>TF</given-names>
              </name>
            </person-group>
            <article-title>Urolithiasis in hyperuricemia and gout.</article-title>
            <source>J Urol</source>
            <year>1981</year>
            <month>Oct</month>
            <volume>126</volume>
            <issue>4</issue>
            <fpage>424</fpage>
            <page-range>424-30</page-range>
            <pub-id pub-id-type="pmid">7288928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r107">
          <label>107</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yu</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>IT</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Tsay</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>WC</given-names>
              </name>
            </person-group>
            <article-title>Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan.</article-title>
            <source>Int J Rheum Dis</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>772</fpage>
            <page-range>772-787</page-range>
            <pub-id pub-id-type="pmid">29363262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23243.r108">
          <label>108</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Janssen</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>TLTA</given-names>
              </name>
              <name>
                <surname>Oude Voshaar</surname>
                <given-names>MAH</given-names>
              </name>
              <name>
                <surname>Vonkeman</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>van de Laar</surname>
                <given-names>MAFJ</given-names>
              </name>
            </person-group>
            <article-title>Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients.</article-title>
            <source>Rheumatol Int</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>37</volume>
            <issue>9</issue>
            <fpage>1435</fpage>
            <page-range>1435-1440</page-range>
            <pub-id pub-id-type="pmid">28748426</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
